Alto Neuroscience, Inc. (ANRO): Entry into a Material Definitive Agreement
Alto Neuroscience, Inc. (ANRO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 tm2620328d1_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 ALTO NEUROSCIENCE, INC. (a Delaware corporation) 3,776,436 Shares of Common Stock UNDERWRITING AGREEMENT Dated: July 13, 2026 ALTO NEUROSCIENCE, INC. (a Delaware corporation) 3,776,436 Shares of Common Stock UNDERWRITING AGRE
How this was made
The 30-second read
Why it matters
This is a financing event. The disclosed share count signals potential dilution, but the excerpt lacks pricing and proceeds, so the exact impact depends on final terms and investor demand.
Market read
A new common stock offering is being set up under a shelf registration, which can drive near-term trading volatility as pricing and dilution expectations crystallize.
What to watch
Traders will need the final prospectus supplement for offering price, underwriter over-allotment, use of proceeds, and any lock-up terms, which are not included in the excerpt.
Background
The 8-K reports Item 1.01, entry into a material definitive agreement, and includes an underwriting agreement tied to a shelf registration statement effective Feb. 11, 2025.
Ticker impact
Alto Neuroscience entered a material definitive underwriting agreement to sell 3,776,436 shares of its common stock.
Likely near-term downside or volatility around deal pricing and execution, with direction depending on offering size versus demand.
The filing is a primary disclosure of an underwriting agreement and share count, but the excerpt does not include gross proceeds, price, or terms that would determine magnitude.
Market effects
Limited read-through; this is company-specific financing rather than a sector-wide catalyst.
Minimal, unless the offering is large enough to affect broader small-cap biotech sentiment.
Low; no cross-border deal or regulatory action is described.
Counterpoint
If the offering is priced attractively and supports cash runway for catalysts, the market may re-rate the stock after initial dilution fears fade.
Key entities
- issuerAlto Neuroscience, Inc.
Company entering the underwriting agreement for a common stock offering.
- underwriterBofA Securities, Inc.
Representative of the underwriters in the underwriting agreement.